Moreover, clinical trials in BRAFV600E melanoma demonstrated promising efficacy and long-lasting antitumor responses with the combined inhibition of BRAF/MEK and PD-1/PD-L1 pathways21–24. The gene discussed is MAP2K7; the disease is melanoma.